Table 2.
Clinicopathologic features of the 489 patients with gastric cancers according to mismatch repair status n (%)
| Total (n = 489) |
MMR |
P value | ||
| Deficient (n = 38) | Intact (n = 451) | |||
| Age (yr) | < 0.0011 | |||
| mean ± SD | 61.0 ± 11.8 | 68.6 ± 9.2 | 60.4 ± 11.7 | |
| Gender | 0.0042 | |||
| Male | 327 (66.9) | 17 (44.7) | 310 (68.7) | |
| Female | 162 (33.1) | 21 (55.3) | 141 (31.3) | |
| Serum CEA (ng/mL) | 0.9101 | |||
| mean ± SD | 36.3 ± 315.7 | 4.4 ± 6.0 | 39.0 ± 328.7 | |
| Tumor size (mm) | 0.8311 | |||
| mean ± SD | 80.3 ± 45.1 | 79.0 ± 38.9 | 80.4 ± 45.6 | |
| Tumor location | 0.0212 | |||
| Fundus and Corpus | 356 (72.8) | 21 (55.3) | 335 (74.3) | |
| Antrum | 133 (27.2) | 17 (44.7) | 116 (25.7) | |
| Histology | 0.0232 | |||
| Differentiated type | 193 (39.5) | 22 (57.9) | 171 (37.9) | |
| Undifferentiated type | 296 (60.5) | 16 (42.1) | 280 (62.1) | |
| Lymphatic invasion | 1.0002 | |||
| Absent | 137 (28.0) | 10 (26.3) | 127 (28.2) | |
| Present | 352 (72.0) | 28 (73.7) | 324 (71.8) | |
| Venous invasion | 0.6092 | |||
| Absent | 281 (57.5) | 20 (52.6) | 261 (57.9) | |
| Present | 208 (42.5) | 18 (47.4) | 190 (42.1) | |
| Primary tumor | 0.6122 | |||
| T2, 3 | 241 (49.3) | 22 (57.9) | 219 (48.6) | |
| T4 | 248 (50.7) | 16 (42.1) | 232 (51.4) | |
| Lymph node involvement | 0.4382 | |||
| N0 | 118 (24.1) | 11 (28.9) | 107 (23.7) | |
| N1, 2, 3 | 371 (75.9) | 27 (71.1) | 344 (76.3) | |
| Distant metastasis | 0.2022 | |||
| M0 | 336 (68.7) | 30 (78.9) | 306 (67.8) | |
| M1 | 153 (31.3) | 8 (21.1) | 145 (32.2) | |
| Stage | 0.8602 | |||
| Stage I, II | 172 (35.2) | 14 (36.8) | 158 (35.0) | |
| Stage III, IV | 317 (64.8) | 24 (63.2) | 293 (65.0) | |
| Residual disease | 0.1612 | |||
| Negative | 375 (76.7) | 33 (86.8) | 342 (75.8) | |
| Positive | 114 (23.3) | 5 (13.2) | 109 (24.2) | |
1
Mann-Whitney U test;
2
Fisher’s exact test. MMR: Mismatch repair; CEA: Carcinoembryonic antigen.